K. Mantwill

Identification of a Conserved Temporal Molecular Response Signature to CDK4/6 Inhibition Through Multi-Omics Integration Across Cancer Cell Lines

Treatment of metastatic breast cancer with CDK4/6 inhibitors in combination with hormone ablation is the current first-line standard of care for this indication, and the therapeutic activity of these inhibitors has been demonstrated in various tumor entities. However, the efficacy of CDK4/6 inhibitor monotherapy is lim...